|
1) Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007; 130: 456-69
|
|
|
|
2) Ferron M, Hinoi E, Karsenty G, et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A. 2008; 105: 5266-70
|
|
|
|
|
|
3) Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009; 94: 45-9
|
|
|
|
|
|
4) Kindblom JM, Ohlsson C, Ljunggren O, et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res. 2009; 24: 785-91
|
|
|
|
|
|
5) Fernandez-Real JM, Izquierdo M, Ortega F, et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab. 2009; 94: 237-45
|
|
|
|
|
|
6) Kanazawa I, Yamaguchi T, Yamamoto M, et al. Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009; 94: 3031-7
|
|
|
|
|
|
7) Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999; 286: 1946-9
|
|
|
|
|
|
8) Ohnaka K, Shimoda S, Nawata H, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun. 2001; 287: 337-42
|
|
|
|
|
|
9) Kanazawa I, Yamaguchi T, Yano S, et al. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol. 2007; 8: 51-62
|
|
|
|
|
|
10) Kanazawa I, Yamaguchi T, Yano S, et al. Activation of AMP-kinase and inhibition of Rho-kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab. 2009; 296: E139-46
|
|
|
|
|
|
11) Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007; 18: 427-44
|
|
|
|
|
|
12) Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166: 495-505
|
|
|
|
|
|
13) Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of bone mineral density or diabetic complications. J Bone Miner Res. 2009; 24: 702-9
|
|
|
|
|
|
14) Yamamoto M, Yamaguchi T, Yamauchi M, et al. Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in type 2 diabetic women. Calcif Tissue Int. 2007; 80: 353-8
|
|
|
|
|
|
15) Saito M, Fujii K, Mori Y, et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006; 17: 1514-23
|
|
|
|
|
|
16) Terada M, Inaba M, Yano Y, et al. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone. 1998; 22: 17–23
|
|
|
|
|
|
17) Botolin S, MacCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006; 99: 411–24
|
|
|
|
|
|
18) Ogawa N, Yamaguchi T, Yano S, et al. The Combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res. 2007; 39: 871–5
|
|
|
|
|
|
19) Yamamoto M, Yamaguchi T, Yamauchi M, et al. Low serum level of the endogenous secretory receptor for advanced glycation end-products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care. 2009; 32: 2263-8
|
|
|
|
|
|
20) Yamamoto M, Yamaguchi T, Yamauchi M, et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93: 1013-9
|
|
|
|
|
|
21) Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94: 2380-6
|
|
|
|
|
|
22) Yamaguchi T, Sugimoto T, Yano S, et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J. 2002; 49: 211-7
|
|
|
|
|
23) Cappuccio FP, Meilahn E, Zmuda JM, et al. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporosis Fractures Research Group. Lancet. 1999; 354: 971-5
|
|
|
|
|
|
24) Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. Am J Hypertens. 2001; 14: 704-7
|
|
|
|
|
|
25) Sennerby U, Melhus H, Gedeborg R, et al. Cardiovascular diseases and risk of hip fracture. JAMA. 2009; 302: 1666-73
|
|
|
|
|
|
26) Holmberg AH, Johnell O, Nilsson PM, et al. Risk factors for fragility fracture in middle age. A prospective population-based study of 33, 000 men and women. Osteoporos Int. 2006; 17: 1065-77
|
|
|
|
|
|
27) Ahmed LA, Schirmer H, Berntsen GK, et al. Features of the metabolic syndrome and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int. 2006; 17: 426-32
|
|
|
|
|
|
28) Kinjo M, Setoguchi S, Solomon DH. Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U. S. sample. J Clin Endocrinol Metab. 2007; 92: 4161-4
|
|
|
|
|
|
29) Yamaguchi T, Kanazawa I, Yamamoto M, et al. Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone. 2009; 45: 174-9
|
|
|
|
|
|
30) Roy DK, O'Neill TW, Finn JD, et al. Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int. 2003; 14: 19-26
|
|
|
|
|
|
31) Meyer HE, Tverdal A, Falch JA. Body height, body mass index, and fatal hip fractures: 16 years' follow-up of 674, 000 Norwegian women and men. Epidemiology. 1995; 6: 299-305
|
|
|
|
|
|
32) Abrahamsen B, Rohold A, Henriksen JE, et al. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabet Med. 2000; 17: 124-9
|
|
|
|
|
|
33) Zhao LJ, Liu YJ, Hamilton J, et al. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab. 2007; 92: 1640-6
|
|
|
|
|